Antonietta Chianca
Overview
Explore the profile of Antonietta Chianca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Brand J, Ruggenenti P, Chianca A, Hofstra J, Perna A, Ruggiero B, et al.
J Am Soc Nephrol
. 2017 May;
28(9):2729-2737.
PMID: 28487395
Guidelines recommend steroid plus cyclical cyclophosphamide (St-Cp) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ESRD. Rituximab (Rtx) may be a safer alternative. In this...
2.
Ruggenenti P, Cravedi P, Chianca A, Caruso M, Remuzzi G
Pediatr Nephrol
. 2016 Oct;
32(2):321-330.
PMID: 27704256
Background: A multidrug treatment strategy that targets urinary proteins with an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) up-titrated to the respective maximum tolerated dose combined with intensified...
3.
Cumberland P, Chianca A, Rahi J
JAMA Ophthalmol
. 2016 May;
134(7):794-801.
PMID: 27197004
Importance: Large-scale generic studies offer detailed information on potential risk factors for refractive error across the life course, but ophthalmic examination in such cases to determine the refractive error phenotype...
4.
Cumberland P, Chianca A, Rahi J
J Cataract Refract Surg
. 2015 Dec;
41(11):2466-75.
PMID: 26703498
Purpose: To evaluate the frequency and distribution of laser refractive surgery in the United Kingdom by sociodemographic factors and outcomes of social participation and well-being. Setting: Six regional recruitment centers...
5.
Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pelle T, Gaspari F, et al.
J Am Soc Nephrol
. 2015 Mar;
26(10):2545-58.
PMID: 25804280
Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic...
6.
Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasa M, et al.
J Am Soc Nephrol
. 2014 Feb;
25(4):850-63.
PMID: 24480824
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic,...
7.
Rurali E, Noris M, Chianca A, Donadelli R, Banterla F, Galbusera M, et al.
Diabetes
. 2013 Jun;
62(10):3599-609.
PMID: 23733198
In patients with diabetes, impaired ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) proteolysis of highly thrombogenic von Willebrand factor (VWF) multimers may accelerate renal and...
8.
Cravedi P, Sharma S, Bravo R, Islam N, Tchokhonelidze I, Ghimire M, et al.
BMJ Open
. 2012 Sep;
2(5).
PMID: 23002161
Objective: To assess the prevalence of microalbuminuria and kidney dysfunction in low-income countries and in the USA. Design: Cross-sectional study of screening programmes in five countries. Setting: Screening programmes in...
9.
Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, et al.
J Am Soc Nephrol
. 2012 Jul;
23(8):1416-25.
PMID: 22822077
Selective depletion of B cells with the mAb rituximab may benefit the autoimmune glomerular disease idiopathic membranous nephropathy (IMN). Here, we describe our experience treating 100 consecutive IMN patients with...